275 related articles for article (PubMed ID: 18343445)
1. Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure.
Ellis RJ; Zhou EH; Fu P; Kaminsky DA; Sodee DB; Faulhaber PF; Bodner D; Resnick MI
J Urol; 2008 May; 179(5):1768-73; discussion 1773-4. PubMed ID: 18343445
[TBL] [Abstract][Full Text] [Related]
2. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer.
Ellis RJ; Kaminsky DA; Zhou EH; Fu P; Chen WD; Brelin A; Faulhaber PF; Bodner D
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):29-34. PubMed ID: 20961696
[TBL] [Abstract][Full Text] [Related]
3. Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer.
Sodee DB; Sodee AE; Bakale G
Semin Nucl Med; 2007 Jan; 37(1):17-28. PubMed ID: 17161036
[TBL] [Abstract][Full Text] [Related]
4. Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer.
Nguyen PL; Whittington R; Koo S; Schultz D; Cote KB; Loffredo M; Tempany CM; Titelbaum DS; Schnall MD; Renshaw AA; Tomaszewski JE; D'Amico AV
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):400-5. PubMed ID: 15145155
[TBL] [Abstract][Full Text] [Related]
5. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer.
Seltzer MA; Barbaric Z; Belldegrun A; Naitoh J; Dorey F; Phelps ME; Gambhir SS; Hoh CK
J Urol; 1999 Oct; 162(4):1322-8. PubMed ID: 10492189
[TBL] [Abstract][Full Text] [Related]
6. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
Nurani R; Wallner K; Merrick G; Virgin J; Orio P; True LD
J Urol; 2007 Nov; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
[TBL] [Abstract][Full Text] [Related]
7. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E
Urology; 2005 Nov; 66(5):1048-53. PubMed ID: 16286122
[TBL] [Abstract][Full Text] [Related]
9. Role of ProstaScint for brachytherapy in localized prostate adenocarcinoma.
Ellis RJ; Kim E; Foor R
Expert Rev Mol Diagn; 2004 Jul; 4(4):435-41. PubMed ID: 15225091
[TBL] [Abstract][Full Text] [Related]
10. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis.
Horwitz EM; Thames HD; Kuban DA; Levy LB; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Hanks GE; Zietman AL
J Urol; 2005 Mar; 173(3):797-802. PubMed ID: 15711272
[TBL] [Abstract][Full Text] [Related]
11. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.
Yu HH; Song DY; Tsai YY; Thompson T; Frassica DA; DeWeese TL
Urology; 2007 Jul; 70(1):111-6. PubMed ID: 17656219
[TBL] [Abstract][Full Text] [Related]
12. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
13. Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT.
Pe ML; Trabulsi EJ; Kedika R; Pequignot E; Dicker AP; Gomella LG; Valicenti RK
Urology; 2009 Jun; 73(6):1328-34. PubMed ID: 19376564
[TBL] [Abstract][Full Text] [Related]
14. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer.
Kupelian PA; Mahadevan A; Reddy CA; Reuther AM; Klein EA
Urology; 2006 Sep; 68(3):593-8. PubMed ID: 16979731
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment predictors of posttreatment PSA doubling times for patients undergoing three-dimensional conformal radiotherapy for clinically localized prostate cancer.
Beard C; Chen MH; Cote K; Loffredo M; Renshaw A; Hurwitz M; D'Amico AV
Urology; 2005 Nov; 66(5):1020-3. PubMed ID: 16286116
[TBL] [Abstract][Full Text] [Related]
16. PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup.
Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
Brachytherapy; 2006; 5(2):122-6. PubMed ID: 16644467
[TBL] [Abstract][Full Text] [Related]
17. Comparison of biochemical failure definitions for permanent prostate brachytherapy.
Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Zelefsky MJ; Pisansky TM; Elshaikh M; Horwitz EM
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1487-93. PubMed ID: 16750326
[TBL] [Abstract][Full Text] [Related]
18. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.
Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Fearn PA; Kattan MW; Stock RG
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1472-7. PubMed ID: 17689026
[TBL] [Abstract][Full Text] [Related]
19. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
Choueiri TK; Dreicer R; Paciorek A; Carroll PR; Konety B
J Urol; 2008 Mar; 179(3):906-10; discussion 910. PubMed ID: 18207194
[TBL] [Abstract][Full Text] [Related]
20. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
